[1]ÁõÑÞ,ʯÀöºì,лÐÂÁ¢,µÈ.18F-FDG PET/CTÔÚδ֪ԭ·¢ÔîÖ×Áö¹ÇתÒÆÕï¶ÏÖеļÛÖµ[J].ÖÐÒ½Õý¹Ç,2020,32(09):39-45.
µã»÷¸´ÖÆ

18F-FDG PET/CTÔÚδ֪ԭ·¢ÔîÖ×Áö¹ÇתÒÆÕï¶ÏÖеļÛÖµ()
·ÖÏíµ½£º

¡¶ÖÐÒ½Õý¹Ç¡·[ISSN:1001-6015/CN:41-1162/R]

¾í:
µÚ32¾í
ÆÚÊý:
2020Äê09ÆÚ
Ò³Âë:
39-45
À¸Ä¿:
Ó°ÏñÕï¶Ï
³ö°æÈÕÆÚ:
2020-09-20

ÎÄÕÂÐÅÏ¢/Info

×÷Õß:
ÁõÑÞʯÀöºìлÐÂÁ¢¶Å±ëº«ÐÇÃô
(Ö£ÖÝ´óѧµÚÒ»¸½ÊôÒ½Ôº,ºÓÄÏ Ö£ÖÝ 450052)
¹Ø¼ü´Ê:
Ö×Áöδ֪ԭ·¢Ôî Ö×ÁöתÒÆ ¹ÇÖ×Áö ·úÍÑÑõÆÏÌÑÌÇF18 Õýµç×Ó·¢Éä¶Ï²ãɨÃè¼°µçÄԶϲãɨÃè
ÕªÒª:
Ä¿µÄ:̽ÌÖ·úÍÑÑõÆÏÌÑÌÇF18(fluorodeoxyglucose F18,18F-FDG)Õýµç×Ó·¢Éä¶Ï²ãɨÃè¼°µçÄԶϲãɨÃè(positron emission tomography and computed tomography,PET/CT)ÔÚδ֪ԭ·¢ÔîÖ×Áö¹ÇתÒÆ(bone metastasis of unknown primary origin,BMUO)Õï¶ÏÖеļÛÖµ¡£·½·¨:Ñ¡ÔñÐÐ18F-FDG PET/CT¼ì²éµÄ223Àýδȷ¶¨Ô­·¢ÔîµÄתÒÆÐÔ¹ÇÖ×Áö»¼ÕߵIJ¡Àý×ÊÁϽøÐзÖÎö¡£ÄÐ122Àý,Å®101Àý¡£ÄêÁä40¡«89Ëê,ÖÐλÊý62Ëê¡£ËùÓÐÄÉÈëÑо¿µÄ»¼Õß¾ùÔÚ³£¹æÓ°Ïñ¼ì²é·¢ÏÖÖ×Áö¹ÇתÒƲ¡Ôîºó3 dÄÚÐÐ18F-FDG PET/CT¼ì²é,²éÕÒÔ­·¢Ö×Áö,²¢Í¨¹ý´©´Ì¡¢ÄÚ¾µ¼ì²é¡¢ÊÖÊõµÈ·½Ê½È¡²¡±ä×éÖ¯±ê±¾½øÐÐ×éÖ¯²¡Àí¼ì²é¡£18F-FDG PET/CT¼ì²é¾ù²ÉÓÃSiemens Biograph Truepoint 64(52»·)PET/CT¡£½á¹û:ÔÚ223Àý»¼ÕßÖÐ,203Àý¾­18F-FDG PET/CT¼ì²éÕï¶ÏΪÑôÐÔ,ÆäÖÐÕæÑôÐÔ199Àý¡¢¼ÙÑôÐÔ4Àý; 20ÀýÕï¶ÏΪÒõÐÔ,ÆäÖÐÕæÒõÐÔ14Àý¡¢¼ÙÒõÐÔ6Àý¡£18F-FDG PET/CTÈ·¶¨BMUOÔ­·¢Ö×ÁöµÄÁéÃô¶ÈΪ97.1%¡¢ÌØÒì¶ÈΪ77.8%¡¢×¼È·¶ÈΪ91.9%¡¢ÑôÐÔÔ¤²âֵΪ98.0%¡¢ÒõÐÔÔ¤²âֵΪ70.0%¡£¼ÙÑôÐÔ¹²4Àý,ÆäÖнáºË2Àý¡¢½á½Ú²¡1Àý¡¢POEMS×ÛºÏÕ÷ 1Àý; ¼ÙÒõÐÔ6Àý,ÆäÖÐθӡ½äϸ°û°©1Àý¡¢Éö͸Ã÷ϸ°û°©1Àý¡¢¼××´ÏÙ°©1Àý¡¢Ç°ÁÐÏÙ°©1Àý¡¢°òë×°©2Àý¡£ 18F-FDG PET/CT¼ì²é¼ì²âµ½ÁËËùÓÐÏÈÇ°ÒÑÖªµÄתÒÆÔî,²¢ÔÚ173Àý»¼ÕßÉíÉÏ·¢ÏÖÁËеÄתÒÆÔî¡£×îÖÕÈ·ÕïµÄ205Àý»¼ÕßÖÐ,·Î°©109Àý(53.2%)¡¢½á³¦°©16Àý(7.8%)¡¢Ê³¹Ü°©13Àý(6.3%)¡¢Ç°ÁÐÏÙ°©9Àý(4.4%)¡¢ÈéÏÙ°©9Àý(4.4%)¡¢Î¸°©8Àý(3.9%)¡¢Âѳ²°©7Àý(3.4%)¡¢Ö±³¦°©7Àý(3.4%)¡¢±ÇÑÊ°©6Àý(2.9%)¡¢ºí°©5Àý(2.4%)¡¢¸Î°©4Àý(2.0%)¡¢ÒÈÏÙ°©4Àý(2.0%)¡¢Éö°©3Àý(1.5%)¡¢°òë×°©2Àý(1.0%)¡¢¶à·¢¹ÇËèÁö2Àý(1.0%)¡¢¼××´ÏÙ°©1Àý(0.5%)¡£°´ÕÕÖ×ÁöµÄ×éÖ¯²¡ÀíѧÀàÐÍ,ÏÙ°©¹²135Àý,Ô¼Õ¼65.8%(135/205)¡£½áÂÛ:18F-FDG PET/CTÊÇÕï¶ÏBMUOÔ­·¢Ö×ÁöµÄÒ»ÖÖ¿É¿¿·½·¨,¿É×÷Ϊ²éÕÒBMUOÔ­·¢²¡ÔîµÄÊ×Ñ¡¼ì²é·½·¨¡£

²Î¿¼ÎÄÏ×/References:

[1] MACEDO F,LADEIRA K,PINHO F,et al.Bone metastases:an overview[J].Oncol Rev,2017,11(1):321.
[2] CENGIZ A,G?KSEL S,Y?REKLI Y.Diagnostic value of 18F-FDG PET/CT in patients with carcinoma of unknown primary[J].Mol Imaging Radionucl Ther,2018,27(3):126-132.
[3] BUDAK E,YANARATE?ÿðþ?‰C? A.Role of(18)F-FDG PET/CT in the detection of primary malignancy in patients with bone metastasis of unknown origin[J].Rev Esp Med Nucl Imagen Mol,2020,39(1):14-19.
[4] BURGLIN SA,HESS S,H?ILUND-CARLSEN PF,et al.18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary:a systematic review and meta-analysis[J].Medicine(Baltimore),2017,96(16):e6713.
[5] ÖìÑÞ·¼,лÐÂÁ¢,ÓÚÑÞϼ,µÈ.18F-FDG PET/CTÏÔÏñSUVmax¶Ô²»Í¬²¡Àí·ÖÐÍÉöϸ°û°©µÄ¼ø±ð¼ÛÖµ[J].Ö£ÖÝ´óѧѧ±¨(ҽѧ°æ),2018,53(6):807-811.
[6] RIAZ S,NAWAZ M K,FARUQUI Z S,et al.Diagnostic accuracy of 18F-Fluorodeoxyglucose positron emission tomography-computed tomography in the evaluation of carcinoma of unknown primary[J].Mol Imaging Radionucl Ther,2016,25(1):11-18.
[7] TAMAM C,TAMAM M,MULAZIMOGLU M.The accuracy of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of bone lesions of undetermined origin[J].World J Nucl Med,2016,15(2):124-129.
[8] TAKAGI T,KATAGIRI H,KIM Y,et al.Skeletal metastasis of unknown primary origin at the initial visit:a retrospective analysis of 286 cases[J].PLoS One,2015,10(6):e0129428.
[9] KWEE T C,BASU S,ALAVI A.PET and PET/CT for unknown primary tumors[J].Methods Mol Biol,2011,727:317-333.
[10] ÆëºìÑÞ,ËïÑ·,°²Èñ.¹ÇתÒÆÁöÓ°Ïñѧ¼ì²é·½·¨¼°Ïà¹Ø½øÕ¹[J].»ªÖпƼ¼´óѧѧ±¨(ҽѧ°æ),2015(1):121-124.
[11] ÄßÊÀ¼Ò.¹ÇתÒÆÁö18F-FDG PET/CT SUVmaxÓëÆä´óС¼°×é֯ѧÀàÐ͵ÄÏà¹ØÐÔÑо¿[D].´óÁ¬:´óÁ¬Ò½¿Æ´óѧ,2018.
[12] ÀîÔ¶,Å£Ïþ»Ô,Ð캣ÈÙ.18F-FDG PET/CTÏÔÏñÔÚ¹ÇתÒÆ°©Õï¶ÏÖеÄÓ¦ÓÃ[J].ɽ¶«Ò½Ò©,2011,51(40):14-16.
[13] YUN M J.Imaging of gastric cancer metabolism using 18F-FDG PET/CT[J].J Gastric Cancer,2014,14(1):1-6.
[14] SON G M,KIM S J.Diagnostic accuracy of F-18 FDG PET/CT for characterization of colorectal focal FDG uptake:a systematic review and meta-analysis[J].Abdom Radiol(NY),2019,44(2):456-463.
[15] WU D,HU Y,WEI Q,et al.Three primary carcinomas on 18F-FDG PET/CT:intrahepatic cholangiocarcinoma,papillary renal cell carcinoma,and clear cell renal cell carcinoma[J].Clin Nucl Med,2018,43(6):428-430.
[16] PARK S B,PARK J M,MOON S H,et al.Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis[J].PLoS One,2018,13(5):e0196808.
[17] ³ÂÆÐÜ¿,ÍõÑ©¾é,ÑîÖ¾.18F-FDG PET/CTÏÔÏñ¶Ô¿ÉÒɼ××´ÏÙÔ­·¢²¡±äµÄÆÀ¹À¼ÛÖµ[J].±ê¼ÇÃâÒß·ÖÎöÓëÁÙ´²,2014,21(1):45-49.
[18] ¶­ÃϽÜ,ÁÖÏéͨ,ÕÔ¾ü,µÈ.17Àý¶ñÐÔÖ×Áö18·úÍÑÑõÆÏÌÑÌÇPETÏÔÏñ¼ÙÒõÐԵķÖÎö[J].ÖлªÖ×ÁöÔÓÖ¾,2006,28(9):713-717.
[19] FRAUM T J,LUDWIG D R,KIM E H,et al.Prostate cancer PET tracers:essentials for the urologist[J].Can J Urol,2018,25(4):9371-9383.
[20] SHARMA A,METE U K,SOOD A,et al.Utility of early dynamic and delayed post-diuretic(18)F-FDG PET/CT SUV(max)in predicting tumour grade and T-stage of urinary bladder carcinoma:results from a prospective single centre study[J].Br J Radiol,2017,90(172):20160787.

ÏàËÆÎÄÏ×/References:

[1]ÂÞÂþÀö,»ÆÂúÓñ,ÀÉý,µÈ.¶àÖÖѪÇåÖ×ÁöÏà¹Ø¿¹Ô­×ÔÉí¿¹ÌåÁªºÏ¼ì²â¶Ô¹ÇÈâÁöµÄÕï¶Ï¼ÛÖµÑо¿[J].ÖÐÒ½Õý¹Ç,2021,33(04):32.
¡¡LUO Manli,HUANG Manyu,LI Dongsheng,et al.A study of the clinical value of combined detection on serum autoantibodies against tumor-associated antigens in the diagnosis of osteosarcomas[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(09):32.

±¸×¢/Memo

±¸×¢/Memo:
ͨѶ×÷Õß:º«ÐÇÃô E-mail:xmhan@zzu.edu.cn
¸üÐÂÈÕÆÚ/Last Update: 2020-09-20